3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Carcinoma, Non-Small-Cell Lung
767
Lung Neoplasms
340
Ovarian Neoplasms
318
Breast Neoplasms
277
Fallopian Tube Neoplasms
158
Triple Negative Breast Neoplasms
144
Small Cell Lung Carcinoma
142
Neoplasms
134
Squamous Cell Carcinoma of Head and Neck
122
Carcinoma, Ovarian Epithelial
114
Neoplasm Metastasis
85
Head and Neck Neoplasms
80
Endometrial Neoplasms
77
Esophageal Neoplasms
71
Uterine Cervical Neoplasms
70
Adenocarcinoma of Lung
69
Neuroblastoma
55
Central Nervous System Neoplasms
52
Carcinoma
50
Lymphoma, Large B-Cell, Diffuse
49
Brain Neoplasms
48
Recurrence
47
Prostatic Neoplasms
44
Parkinson Disease 4, Autosomal Dominant Lewy Body
44
Urinary Bladder Neoplasms
42
Esophageal Squamous Cell Carcinoma
41
Lymphoma
39
Melanoma
35
Carcinoma, Squamous Cell
33
Lymphoma, Non-Hodgkin
31
Interventions
Paclitaxel
10
trametinib
9
dabrafenib
9
pembrolizumab
5
lenvatinib
5
fosbretabulin
4
Sorafenib
4
Radiotherapy, Intensity-Modulated
4
Doxorubicin
4
Radiotherapy
3
Cisplatin
3
pazopanib
2
efatutazone
2
combretastatin
2
cobimetinib
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Vemurafenib
2
Trastuzumab
2
Taxes
2
Nivolumab
2
Gefitinib
2
Filgrastim
2
Everolimus
2
Docetaxel
2
Carboplatin
2
Bevacizumab
2
zimberelimab
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Thyroid Carcinoma, Anaplastic
×
Carboplatin
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn